BreadcrumbHome / Investors / Press Releases Press Releases Jump Links - All Pages OverviewPress ReleasesEvents and PresentationsSEC FilingsCorporate GovernanceStock Information Keyword Search Year None20242023202220212020201920182017201620152014 April 18, 2024 Ocular Therapeutix™ Announces Positive Topline Phase 1 Data for AXPAXLI™ in Diabetic Retinopathy April 16, 2024 Ocular Therapeutix™ Strengthens Clinical Team with Appointment of Key Retinal Leaders April 15, 2024 Ocular Therapeutix™ Executive Chairman Pravin U. Dugel, MD Becomes President and CEO Antony Mattessich is Stepping Down as President and CEO April 9, 2024 Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Senior Vice President of Global Head of Biometrics April 6, 2024 Ocular Therapeutix™ Announces Positive Phase 2 PAXTRAVA™ Glaucoma Data at the American Society of Cataract and Refractive Surgery 2024 Annual Meeting March 26, 2024 Ocular Therapeutix™ To Present Data at the 2024 ASCRS Annual Meeting (American Society of Cataract and Refractive Surgery) March 11, 2024 Ocular Therapeutix™ Reports Fourth Quarter and Full Year 2023 Results March 5, 2024 Ocular Therapeutix™ to Release Fourth Quarter and Full Year 2023 Results on March 11, 2024 February 22, 2024 Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Executive Chairman and Chief Strategy Officer February 22, 2024 Ocular Therapeutix, Inc. Announces $325.0 Million Private Placement February 22, 2024 Ocular Therapeutix™ Announces Board of Directors and Leadership Updates February 15, 2024 Ocular Therapeutix™ Appoints Steve Meyers to Chief Commercial Officer February 13, 2024 Ocular Therapeutix™ Announces First Subjects Screened in Phase 3 Pivotal Clinical Trial of AXPAXLI™ in Wet AMD January 25, 2024 Ocular Therapeutix™ Announces FDA Agreement to Amend Special Protocol Assessment (SPA) for Pivotal Clinical Trial of AXPAXLI™ in Wet AMD Additional Resources Investor FAQsInformation Request
Keyword Search Year None20242023202220212020201920182017201620152014 April 18, 2024 Ocular Therapeutix™ Announces Positive Topline Phase 1 Data for AXPAXLI™ in Diabetic Retinopathy April 16, 2024 Ocular Therapeutix™ Strengthens Clinical Team with Appointment of Key Retinal Leaders April 15, 2024 Ocular Therapeutix™ Executive Chairman Pravin U. Dugel, MD Becomes President and CEO Antony Mattessich is Stepping Down as President and CEO April 9, 2024 Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Senior Vice President of Global Head of Biometrics April 6, 2024 Ocular Therapeutix™ Announces Positive Phase 2 PAXTRAVA™ Glaucoma Data at the American Society of Cataract and Refractive Surgery 2024 Annual Meeting March 26, 2024 Ocular Therapeutix™ To Present Data at the 2024 ASCRS Annual Meeting (American Society of Cataract and Refractive Surgery) March 11, 2024 Ocular Therapeutix™ Reports Fourth Quarter and Full Year 2023 Results March 5, 2024 Ocular Therapeutix™ to Release Fourth Quarter and Full Year 2023 Results on March 11, 2024 February 22, 2024 Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Executive Chairman and Chief Strategy Officer February 22, 2024 Ocular Therapeutix, Inc. Announces $325.0 Million Private Placement February 22, 2024 Ocular Therapeutix™ Announces Board of Directors and Leadership Updates February 15, 2024 Ocular Therapeutix™ Appoints Steve Meyers to Chief Commercial Officer February 13, 2024 Ocular Therapeutix™ Announces First Subjects Screened in Phase 3 Pivotal Clinical Trial of AXPAXLI™ in Wet AMD January 25, 2024 Ocular Therapeutix™ Announces FDA Agreement to Amend Special Protocol Assessment (SPA) for Pivotal Clinical Trial of AXPAXLI™ in Wet AMD
April 18, 2024 Ocular Therapeutix™ Announces Positive Topline Phase 1 Data for AXPAXLI™ in Diabetic Retinopathy
April 15, 2024 Ocular Therapeutix™ Executive Chairman Pravin U. Dugel, MD Becomes President and CEO Antony Mattessich is Stepping Down as President and CEO
April 9, 2024 Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Senior Vice President of Global Head of Biometrics
April 6, 2024 Ocular Therapeutix™ Announces Positive Phase 2 PAXTRAVA™ Glaucoma Data at the American Society of Cataract and Refractive Surgery 2024 Annual Meeting
March 26, 2024 Ocular Therapeutix™ To Present Data at the 2024 ASCRS Annual Meeting (American Society of Cataract and Refractive Surgery)
March 5, 2024 Ocular Therapeutix™ to Release Fourth Quarter and Full Year 2023 Results on March 11, 2024
February 22, 2024 Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Executive Chairman and Chief Strategy Officer
February 13, 2024 Ocular Therapeutix™ Announces First Subjects Screened in Phase 3 Pivotal Clinical Trial of AXPAXLI™ in Wet AMD
January 25, 2024 Ocular Therapeutix™ Announces FDA Agreement to Amend Special Protocol Assessment (SPA) for Pivotal Clinical Trial of AXPAXLI™ in Wet AMD
